Department of Rheumatic Diseases (470), Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Rheumatology (Oxford). 2013 Aug;52(8):1500-8. doi: 10.1093/rheumatology/ket166. Epub 2013 May 8.
The introduction of effective treatment strategies in the past two decades has changed the management of RA dramatically. The objective was to analyse the changes in disease activity, function, joint damage and incidence of orthopaedic surgery over a period of 20 years (1989-2009) for patients with RA.
Data acquired from 1989 to 2008 inclusive from the Nijmegen RA inception cohort were studied. By repeated measures analysis the course of the population mean disease activity score (DAS28) and the Health Assessment Questionnaire-Disability Index (HAQ-DI) corrected for age, gender, RF and disease duration was determined. Orthopaedic interventions were analysed as incidence rates with a Poisson distribution. We calculated the prevalence of the various therapies that patients were receiving.
By 2009, 992 patients with RA had been included and 273 had been excluded. From 1989 onwards, the proportion of patients using MTX increased from 5% (8 of 164) to 62% (486 of 780), and biologic response modifiers from 0% to 22% (168 of 780) in 2008. The average MTX dosage increased to 16.1 ± 5.5 mg/week in 2008. The mean DAS28 (3.1) and HAQ-DI (0.47) were least (P < 0.008) in 2008 compared with previous years. There was a significant trend towards lower incidence rates of orthopaedic intervention in the period 2006-2008 than in almost all previous years.
Treatment strategy changed in a large inception cohort of patients with RA which coincided with decreased disease activity, increased functional ability and fewer orthopaedic interventions since the early 1990s.
在过去的二十年中,引入了有效的治疗策略,极大地改变了 RA 的治疗方法。本研究的目的是分析 1989 年至 2009 年期间,类风湿关节炎(RA)患者的疾病活动度、功能、关节损伤和骨科手术发生率的变化。
研究纳入了 1989 年至 2008 年期间尼美根 RA 起始队列的数据。通过重复测量分析,确定了人群平均疾病活动评分(DAS28)和经年龄、性别、RF 和疾病持续时间校正后的健康评估问卷残疾指数(HAQ-DI)的变化过程。采用泊松分布分析骨科干预的发生率。我们计算了患者接受各种治疗的患病率。
到 2009 年,共纳入了 992 例 RA 患者,排除了 273 例患者。自 1989 年以来,MTX 的使用率从 5%(164 例中的 8 例)增加到 2008 年的 62%(780 例中的 486 例),生物制剂的使用率从 0%增加到 22%(780 例中的 168 例)。2008 年 MTX 的平均剂量增加到 16.1±5.5mg/周。与前几年相比,2008 年 DAS28(3.1)和 HAQ-DI(0.47)平均值最低(P<0.008)。2006 年至 2008 年期间,骨科干预的发生率呈显著下降趋势,明显低于前几年。
自 20 世纪 90 年代初以来,RA 大型起始队列患者的治疗策略发生了变化,这与疾病活动度降低、功能能力提高和骨科干预减少有关。